# Zealand Pharma Reports DKK 4,529 Million Q3 Revenue and Starts Phase 3 Petrelintide Program With Roche

> Zealand Pharma reported DKK 4,529 million in Q3 revenue and DKK 3,267 million operating profit, and began a Phase 3 petrelintide program with Roche.

- Published: 2026-11-12T06:54:03+00:00
- Section: Earnings & Results
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-12/zealand-pharma-q3-revenue-phase-3
- Source: [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/12/3401221/0/en/zealand-pharma-announces-financial-results-for-the-first-nine-months-of-2026.html)

## Key takeaways

- Zealand Pharma reported Q3 2026 revenue of DKK 4,529 million and operating profit of DKK 3,267 million.
- Zealand and Roche initiated a Phase 3 registrational program for petrelintide with three trials and about 7,000 participants.
- Zealand narrowed its 2026 operating expense guidance to DKK 2.7-3.0 billion from DKK 2.7-3.3 billion.

Zealand Pharma reported revenue of DKK 4,529 million and an operating profit of DKK 3,267 million for the third quarter of 2026, and said it had started a Phase 3 registrational program for petrelintide with Roche. The Danish biotechnology company, which develops peptide-based treatments for obesity and metabolic disease, published the figures in its interim report for the nine months ended September 30, 2026, [announced via GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/12/3401221/0/en/zealand-pharma-announces-financial-results-for-the-first-nine-months-of-2026.html).

## Zealand and Roche Begin Petrelintide Phase 3

[Zealand Pharma](https://akta.pro/company-profiles/0000s1s/zealand-pharma) said the Phase 3 program for petrelintide, an amylin analog, consists of three registrational trials expected to enroll approximately 7,000 participants in total. The company also reported positive topline results from the Phase 2 ZUPREME-2 trial in people with overweight or obesity and type 2 diabetes, where petrelintide delivered up to 9.2% weight loss at week 28 and HbA1c reductions of up to 0.65% from a mean baseline of 7.7%.

[Roche](https://akta.pro/company-profiles/00000om/roche) and Zealand entered a global collaboration and license agreement in March 2025 to co-develop and co-commercialize petrelintide and combination products, including a fixed-dose combination of petrelintide and Roche's CT-388, according to akta.pro [company records](https://akta.pro/company-data). The two companies expect to initiate the Phase 2 ZYNERGY trial of the fixed-dose combination in people with overweight or obesity in the fourth quarter of 2026.

Adam Steensberg, President and Chief Executive Officer at Zealand Pharma, said: "This quarter, we made progress on every commitment in our Metabolic Frontier 2030 strategy." He added that "petrelintide moves closer to offering a differentiated treatment option and weight management experience."

## Zealand's Cash and Buyback Figures

Company records show Zealand's cash position stood at DKK 13,509 million at September 30, 2026, down from DKK 15,109 million at December 31, 2025. The company completed a share buy-back program initiated on May 7, 2026, repurchasing 4,408,500 shares at a total gross value of DKK 1,300 million. Zealand narrowed its 2026 operating expense guidance excluding other operating items to DKK 2.7-3.0 billion from DKK 2.7-3.3 billion, while keeping its collaboration revenue guidance of DKK 4.5 billion unchanged.

## Earlier ZP9830 and Generate Deals

In October 2026, Zealand Pharma announced positive topline results from the multiple ascending dose part of a Phase 1 trial with its Kv1.3 ion channel blocker ZP9830, which was well tolerated in 32 healthy participants, GlobeNewswire reported. That month, Longevity.Technology reported that Zealand and Generate Biomedicines signed a collaboration to design multispecific protein therapeutics for metabolic diseases, with nearly $1.2 billion in milestones.

## Glepaglutide and Dasiglucagon Decisions Ahead

Zealand expects a final decision on the EU Marketing Authorization Application for Zeydovio (glepaglutide) in short bowel syndrome in the fourth quarter of 2026, after the Committee for Medicinal Products for Human Use recommended approval. The company also expects to resubmit the New Drug Application for dasiglucagon in congenital hyperinsulinism to the U.S. Food and Drug Administration in the fourth quarter of 2026.

## Companies in this story

- [Zealand Pharma company profile](https://akta.pro/company-profiles/0000s1s/zealand-pharma) · website: http://www.zealandpharma.com
- [Roche company profile](https://akta.pro/company-profiles/00000om/roche) · website: http://www.roche.com
- [Royalty Pharma company profile](https://akta.pro/company-profiles/0000alx/royalty-pharma) · website: http://royaltypharma.com

---
News for Agent · https://newsforagent.com/llms.txt